Based on the Paradigm Biopharmaceuticals Limited stock forecast from 0 analysts, the average analyst target price for Paradigm Biopharmaceuticals Limited is not available over the next 12 months. Paradigm Biopharmaceuticals Limited’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Paradigm Biopharmaceuticals Limited is Very Bearish, which is based on 0 positive signals and 6 negative signals. At the last closing, Paradigm Biopharmaceuticals Limited’s stock price was USD 0.1147. Paradigm Biopharmaceuticals Limited’s stock price has changed by +0.00% over the past week, -33.24% over the past month and -75.16% over the last year.
No recent analyst target price found for Paradigm Biopharmaceuticals Limited
No recent average analyst rating found for Paradigm Biopharmaceuticals Limited
Company Overview Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia. Read Less
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river vir...Read More
Frequently Asked Questions About Paradigm Biopharmaceuticals Limited (PBIGF) Stock
Stock Target Advisor's fundamental analysis for Paradigm Biopharmaceuticals Limited's stock is Very Bearish.
Unfortunately we do not have enough data on PBIGF's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on PBIGF's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on PBIGF's stock to indicate if its overvalued.
The last closing price of PBIGF's stock was USD 0.11.
The most recent market capitalization for PBIGF is USD 0.05B.
Unfortunately we do not have enough analyst data on PBIGF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Paradigm Biopharmaceuticals Limited's stock.
As per our most recent records Paradigm Biopharmaceuticals Limited has 0 Employees.
Paradigm Biopharmaceuticals Limited's registered address is 500 Collins Street, Melbourne, VIC, Australia, 3000.
You can get more information about it from Paradigm Biopharmaceuticals Limited's website at https://www.paradigmbiopharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Paradigm Biopharmaceuticals Limited (PBIGF) Stock
Stock Target Advisor's fundamental analysis for Paradigm Biopharmaceuticals Limited's stock is Very Bearish.
Unfortunately we do not have enough data on PBIGF's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on PBIGF's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on PBIGF's stock to indicate if its overvalued.
The last closing price of PBIGF's stock was USD 0.11.
The most recent market capitalization for PBIGF is USD 0.05B.
Unfortunately we do not have enough analyst data on PBIGF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Paradigm Biopharmaceuticals Limited's stock.
As per our most recent records Paradigm Biopharmaceuticals Limited has 0 Employees.
Paradigm Biopharmaceuticals Limited's registered address is 500 Collins Street, Melbourne, VIC, Australia, 3000.
You can get more information about it from Paradigm Biopharmaceuticals Limited's website at https://www.paradigmbiopharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PBIGF !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Join over half-million smart investors across the world
Loading...
The Adjusted Closing and Unadjusted Closing sections display stock prices with and without adjustments, respectively. The Share Trading Volume section shows the stocks trading volume over time, indicating market activity. The Compare Performance section allows you to analyze a stocks performance against others by entering symbols and clicking Add to see relative returns. These tools aid in making informed investment decisions. Use the date range selectors to view trends from the past month (1m), three months (3m), six months (6m), year-to-date (YTD), one year (1y), five years (5y), or all available data (All).
